fda compounding semaglutide enforcement november 2025 Important Update: Changes to Compounded Availability FDA to Restrict Ingredients Used

However, published case reports and a 2024 retrospective cohort in Thyroid (N=112 patients on stable levothyroxine who started semaglutide) found that 28% required a TSH recheck within 6 months because of new hypothyroid symptoms or rising TSH, compared with 9% in a matched control group not starting GLP-1 therapy [7]

If they were administered recently, they are more likely to appear in tests

Over 90% of participants in the 12mg group lost at least 10% of their body weight

GLP-1 drugs have lower hypoglycemia risk and promote weight loss but commonly cause nausea, vomiting, and other GI symptoms

TRIUMPH-1 and TRIUMPH-2 are the pivotal trials

When taken orally, peptides are rapidly broken down by digestive enzymes in the stomach and small intestine before they can be absorbed into the bloodstream in meaningful quantities